SUMMARY To develop a more specific plasma test for myocardial infarction, antibodies specific for cardiac myosin light chains (CM-LC) were elicited that showed less than 3% cross-reactivity with skeletal muscle light chains. These antibodies were used to develop a radioimmunoassay for CM-LC that had a sensitivity of 20 ng (+ 4 SD; P < 0.001). Normal dog plasma showed no measurable concentrations of CM-LC (n = 6). Plasma samples from 10 However, normal human plasma has been shown to contain some CK-MB and the antiserum raised in response to the BB isoenzyme also reacts with enzyme from brain.' Another RIA that has been developed for detection of MI is specific for myoglobin.3 Skeletal and cardiac muscle myoglobin are structurally and immunologically identical.4 A variety of injuries to skeletal muscle, as well as strenuous exercise, release measurable amounts of myoglobin into the circulation.5
(247.0 ± 35.28 ng/ml) and in another dog at 120 hours (245 ng/ml). Histochemical infarct size was determined to be 0.5-10% of the left ventricular mass at seven days by triphenyltetrazolium chloride staining. The specificity and sensitivity of this radioimmunoassay for detection of CM-LC, unique proteins to the heart, may be valuable in the diagnosis of myocardial infarction.
THE NEED FOR A SENSITIVE and specific diagnostic test for myocardial infarction (MI) has prompted development of various radioimmunoassays (RIA) for proteins released by the damaged myocardial cells into the circulation after myocardial infarction. -3 The most sensitive and specific RIA detects creatine kinase-MB (CK-MB) isoenzyme." 2 However, normal human plasma has been shown to contain some CK-MB and the antiserum raised in response to the BB isoenzyme also reacts with enzyme from brain.' Another RIA that has been developed for detection of MI is specific for myoglobin.3 Skeletal and cardiac muscle myoglobin are structurally and immunologically identical.4 A variety of injuries to skeletal muscle, as well as strenuous exercise, release measurable amounts of myoglobin into the circulation. 5 Cardiac myosin light chains (CM-LC) are structurally6' and immunologically8 different from skeletal myosin light chains, and thus may provide a unique cardiac-specific antigen. We now report the development of a sensitive RIA specific for CM-LC and the detection of CM-LC in serum from dogs after experimental MI. Trahern and coworkers have reported the application of a RIA for human CM-LC in the diagnosis of myocardial infarction.9
Materials and Methods
Purification of CM-LC Cardiac myosin was extracted from canine left ventricular myocardium according to the procedure of Katz et al.'0 The purified myosin was then precipitated in 10 volumes of cold H2O, and light chains were extracted and separated from heavy chains by the procedure of Perrie and Perry. 7 The cold H,O precipitated myosin was redissolved in 5 M guanidine-HC I at 4°C and allowed to stand at the same temperature for 3 hours. Heavy chains were then precipitated by addition of 1 volume of cold distilled H,O and 4 volumes of cold absolute ethanol at 4°C. The precipitate was removed by centrifugation at 10,000 X g at 4°C and discarded. The supernatant solution containing CM-LC was dialyzed against 20 volumes 30 mM KCl, 25mM Tris-HCl, pH 7.6, 1 mM EDTA. Sodium dodecyl sulfate gel electrophoresis of the supernatant material in a discontinuous buffer system of Neville," with 10% acrylamide gels demonstrated only the two myosin light chains ( fig. 1 ) without heavy chain contamination. Skeletal muscle myosin light chains from gluteus muscles were also prepared by the same procedure.
Immunization
Purified CM-LC (1 mg/ml) was emulsified in an equal volume of complete Freund's adjuvant and injected intradermally and into the toe pads of six New Zealand white rabbits as previously described.'2 13 A dose of 500 Ag/rabbit was used for the primary immunization, followed three and five weeks later by booster immunizations of 400 jig and 300 ,ug of CM-LC, respectively. One week after the final injection, 50 ha" #S ;in. CM-LC were radiolabeled with iodine-125 by the lactoperoxidase procedure of Marchalonis,"5 using carrier-free 125I. Iodine-labeled CM-LC (125I-CM-LC) were separated from free iodide by Sephadex G-25 (Phamacia Fine Chemicals, Inc., Piscataway, NJ) gel filtration on a 0.5 X 10 cm column prewashed with 1.5 ml of 1% bovine serum albumin (Pentex Biochemical, Kankakee, Ill.) in 0.3 M Na phosphate, pH 7.0, 0.15 M NaCl (PBS) to reduce nonspecific absorption of '25I-CM-LC to the column matrix. '251-CM-LC were eluted with PBS and appeared in the void volume. They were either used immediately or stored at -200C.
Determination of Antibody Titer
To 100 ,il of 1% bovine serum albumin in PBS, 10 Ml of antiserum diluted in PBS was added, followed by 10,000 cpm aliquots of 1251-CM-LC in 10 ,tl of PBS. The reaction mixture was mixed by vortex mixer and incubated at 4°C overnight. Bound and free anti-CM-LC were separated by addition of 10 ,ul of 1 mg/ml nonimmune rabbit IgG and 25-100 Al of goat antirabbit IgG serum. The reaction mixture was incubated at 37°C for 1 hour, then centrifuged in a refrigerated centrifuge (500 X g). After washing three times with 0.5 ml PBS, the precipitate (a) and the supernatant and washes (b) were counted in a gamma scintillation counter (Packard Auto-Gamma Scintillation Spectrometer). Percent bound was obtained by the following equation: ( a ) X 100. Controls were treated in a +b the same way, except that serial dilutions of normal rabbit serum were substituted for immune serum. All determinations were performed in 10 x 60 mm Falcon tubes in duplicate.
Radioimmunoassay to CM-LC Radioimmunoassays using both equilibrium and nonequilibrium methods were devised for rabbit anti-CM-LC serum. Each assay was performed in duplicate; a standard curve set of standards were assayed with each unknown group.
Equilibrium Method
One hundred microliters of 1% bovine serum albumin in PBS were added to I x 6 cm Falcon disposable test tubes and vortexed briefly to ensure even coating of the inner vessel walls. Aliquots of CM-LC (1, 2.5, 5, 10, 25, 50, 100, 250, 500 and 1000 ng), each in 10 ul PBS, were added to 10 jl of a 1:10 dilution of rabbit anti-CM-LC serum, followed by 10 Al PBS containing 10,000 cpm of '25I-CM-LC. The contents of the tubes were mixed by vortexing and then incubated at 4°C overnight. Bound and free '251-CM-LC were separated by the double antibody method described in the preceding section. Assays of serum or plasma samples (400 jAl) were compared to standards to which 400 Ml of normal dog serum or plasma had been added. The total time required for this assay is less than 24 hours.
Accelerated Nonequilibrium Method
The assay was carried out as described above, except standards or unknowns were incubated with antiserum for 1 hour at 37°C. 1251-CM-LC was then added, followed by a second hour of incubation at 37°C. Bound and free 1251-CM-LC were separated by the double antibody method. Infarct size was determined from the photographs of the histochemically (TTC) stained ventricular slices in six of the dogs in the reperfusion study. Using a computer-based planimetry system, infarct area, volume and weight were calculated for each left ventricular slice and in turn for each left ventricle. All infarcts sized in this study are reported as percentage of the total left ventricular mass infarcted.
Statistical Analysis
Standard competitive binding curves and competitive binding data were calculated employing the log-logit method described by Rodbard and coworkers. '9 Results In a representative antibody titer determination of CM-LC antiserum, a 10 ,1u aliquot of undiluted antiserum bound 54% of 1251-CM-LC added. At 1/10 dilution, 50%, and at 1/20 dilution 22%, of the label was bound. In all subsequent assays, a 1/10 dilution of the antiserum was employed. 3% cross-reactivity. The range of cross-reactivity among five antisera tested was between 2.9-10%. Antisera exhibiting cross-reactivity of greater than 4% were not used.
As demonstrated in figure 3, normal dog sera had no significant inhibitory effect on the binding of 1251_ CM-LC to antibody when 400 ,l was added to each tube. Sera from four dogs subjected to thoracotomy and with attendant skeletal muscle damage, but not coronary ligation, were tested for cross-reacting CM-LC, but none was found. Figure 4 shows the evolution of plasma CM-LC concentration in a representative dog subjected to LAD occlusion. Serial sham-operated animal, nor at 0, 2 and 4 hours in the animal with coronary occlusion and histologically confirmed myocardial infarction (± 4 SD, P < 0.001). However, the 6-hour plasma sample from the coronary occlusion animal showed 38% inhibition of maximal binding of 125I-CM-LC, indicating a concentration of 43 ng/ml. The peak concentration of CM-LC occurred at 24 hours, had declined by 48 hours, but was still measurable at 72 hours. In the reperfusion model, CM-LC was detected in serum samples from some animals after 5 hours of occlusion, before reperfusion. Figure 5 plots CM-LC concentrations in a representative animal. Reperfusion did not result in an immediate increase of CM-LC concentration. A maximum of 170 ng/ml was reached at 24 hours, and returned to undetectable levels at 168 hours.
Serum concentration of CM-LC in 10 dogs with 5 hours of coronary occlusion followed by reperfusion is Al:-+-II I T.. eC 1n 1) f""f T ' -%.,.I sion. Peak levels of CM-LC usually occurred 24-96 hours after reperfusion. In one dog, two peaks of CM-LC were observed, one at 18 hours (182.5 ng/ml) and the other at 120 hours (245 ng/ml). Nine of the 10 animals subjected to histological study had myocardial infarcts. One dog was not sacrificed. The mass of the infarct was estimated in six animals by the tetrazolium staining method and related to left ventricular mass. Table 4 compares CM-LC concentrations with infarct size. Infarcts as small as 0.5% of left ventricular mass were readily detected by elevation of serum CM-LC concentration. In this group, however, there appears to be no discernible relationship between time of appearance of measurable serum concentrations of CM-LC, time of peak concentration or maximal concentration with infarct size. concentration. 3) Release of CM-LC occurs early (4-6 hours) and may be persistent (longer than seven days).
At this early stage of development of this method, several problems are unresolved: 1) The sensitivity of the RIA is not great enough to detect normal circulating levels of CM-LC, if they exist. An increase in sensitivity may permit still earlier detection of infarction, as well as detection of very small infarcts. 2) Antibody concentration in antiserum has been low in all rabbits tested, so that the serum must be used in 1:10 dilution. 3) So far, a relationship is not apparent from these limited studies between either time of first appearance, time of peak concentration or maximal concentration of CM-LC with infarct size. However, additional studies are required to obtain a more precise analysis of the exact relationship between peak CM-LC concentration, time of first appearance, total CM-LC and infarct size.
